News

CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.

Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE). The stock trades at $24.37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026. Yet the dividend keeps coming. I want to know if that 7.27% yield is a gift or a warning. The Dividend ... This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios

It could prove to be a case of better later than never for the healthcare giant.

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.

Is PFE a good stock to buy? We came across a bullish thesis on Pfizer Inc. on r/ValueInvesting by Dismal-Cancel4958. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.08 as of June 22nd. PFE’s trailing and forward P/E were 19.15 and 8.50 respectively according to Yahoo Finance. Pfizer […]

This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb: ... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target

Pfizer Inc. (NYSE:PFE) is among the Best Healthcare Stocks. On June 23, Reuters reported that Pfizer Inc. (NYSE:PFE) ‘s Chief International Commercial Officer, Alexandre de Germay, said China has moved ahead of Europe in pharmaceutical innovation and drug development. De Germay commented that China now has “40% of all clinical studies in oncology” globally. He pointed […]

Things are going from bad to worse for the pharmaceutical giant.

Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court found there was not enough evidence to support claims of Pfizer's involvement in alleged collusion. The dismissal removes a legal overhang tied to long running litigation involving multiple generic drugmakers. Pfizer is a large global pharmaceutical company with a portfolio spanning prescription medicines, vaccines, and other healthcare products. For investors...

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.

The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.

Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Keybanc said Nike’s outlook is further clouded by growing uncertainty around operations in China and EMEA, as well as management transition.

Pfizer's CFO joins Nike, Wendy's hires Potbelly Sandwiches' CFO, Airwallex's new CFO boomerangs back to the company and more.

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

David Denton will replace Matthew Friend, who will remain at the company until 4 September to assist with the handover.

Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.”

Earlier this week, Pfizer reported that its Phase 3 SigVie-002 trial of sigvotatug vedotin in previously treated non-squamous non-small cell lung cancer failed to show a statistically significant overall survival benefit over docetaxel in the overall population, while the U.S. FDA approved IBRANCE as a maintenance option for adults with HR-positive, HER2-positive advanced or metastatic breast cancer following induction therapy. Together, the mixed lung cancer data and the expanded IBRANCE...

In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.

The U.S. Food and Drug Administration approved the use of Ibrance as maintenance treatment for adults with a specific type of advanced or metastatic breast cancer on Wednesday.